You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Swiss firm DKSH will market and sell Ubiquitome's Liberty16 PCR-based platform in Australia, New Zealand, and other countries in the region.
The company has proposed developing a diagnostic test that simultaneously detects specific biomarkers associated with different stages of SARS-CoV-2.
The PCR-based test works with upper and lower respiratory specimens, including nasal swabs and sputum, and can be performed by high complexity labs.
The test is designed to detect circulating neutralizing antibodies against the virus without the need for live biological materials or biosafety containment.
Takeda's financial contribution will enable the International Atomic Energy Agency to ramp up its initiative to supply RT-PCR tests to laboratories globally.
The test is designed to detect the E and RdRp genes of SARS-CoV-2 in various respiratory specimens including nasopharyngeal swabs and nasal aspirates.
The cancer test developer will use the funding to commercialize its enrichment-based NGS panels. An IVD test also got CE marked.
The PCR-based tests are designed to detect the SARS-CoV-2 nucleocapsid gene in various respiratory specimens including oropharyngeal swabs.
The Shanghai-based molecular diagnostics firm is working with the Shanghai Zhongshan Hospital and other medical centers to enroll patients into the PREDICT trial.
The deal marks the 10th distribution agreement Australia-based Sienna has signed for its test, including one covering Finland earlier this year.